Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 12/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971822 | 1.00 | MBOAT4 (0.64) | MBOAT4OPRK1MAP3K12CHRM4FAAH | |
| SCHEMBL16699213 | 0.95 | MBOAT4 (0.69) | MBOAT4OPRK1CHRM4FAAHIDO1 | |
| SCHEMBL18166107 | 0.87 | MBOAT4 (0.71) | MBOAT4OPRK1 | |
| SCHEMBL19971808 | 0.87 | MBOAT4 (0.71) | MBOAT4OPRK1 | |
| SCHEMBL19971809 | 0.87 | MBOAT4 (0.71) | MBOAT4OPRK1 | |
| SCHEMBL18166117 | 0.86 | MBOAT4 (0.59) | MBOAT4FAAH | |
| SCHEMBL19971844 | 0.86 | MBOAT4 (0.81) | MBOAT4OPRK1 | |
| SCHEMBL19971843 | 0.86 | MBOAT4 (0.81) | MBOAT4OPRK1 | |
| SCHEMBL18166114 | 0.84 | MBOAT4 (0.66) | MBOAT4OPRK1FAAH | |
| SCHEMBL16728368 | 0.83 | MBOAT4 (0.77) | MBOAT4OPRK1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885OPRK1 3962/4885MAP3K12 4331/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885OPRK1 3962/4885MAP3K12 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.